Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 03:08:33 +0200Fri, 31 May 2024 12:00:00 +0200Summary of opinion: Skyrizi, 30/05/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/skyriziSummary of opinion: Skyrizi, 30/05/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/skyriziFri, 31 May 2024 12:00:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 22, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/skyriziHuman medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 22, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/skyriziFri, 24 May 2024 15:45:00 +0200Human medicineSkyrizi : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4759-en_1.pdfSkyrizi : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4759-en_1.pdfFri, 24 May 2024 11:47:00 +0200Human medicine